NEW YORK (GenomeWeb) – Australian molecular diagnostics company SpeeDx said it has received a A$2.5 million ($2 million) grant from the New South Wales Medical Devices Fund (MDF) to support the continued rollout of its multiplex molecular diagnostic ResistancePlus MG test.

Separately, it also announced a distribution deal with Scandinavian clinical laboratory supplier Diagen. 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.